Trial Profile
A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Relugolix (Primary) ; LHRH receptor antagonists
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 07 Dec 2023 Status changed from active, no longer recruiting to completed.
- 12 Sep 2023 Planned End Date changed from 20 May 2024 to 26 Oct 2023.
- 12 Sep 2023 Planned primary completion date changed from 2 Apr 2024 to 25 Oct 2023.